Vascular mechanotransduction

MJ Davis, S Earley, YS Li, S Chien - Physiological reviews, 2023 - journals.physiology.org
This review aims to survey the current state of mechanotransduction in vascular smooth
muscle cells (VSMCs) and endothelial cells (ECs), including their sensing of mechanical …

Ribosome biogenesis in disease: new players and therapeutic targets

L Jiao, Y Liu, XY Yu, X Pan, Y Zhang, J Tu… - … and Targeted Therapy, 2023 - nature.com
The ribosome is a multi-unit complex that translates mRNA into protein. Ribosome
biogenesis is the process that generates ribosomes and plays an essential role in cell …

Emerging roles and mechanism of m6A methylation in cardiometabolic diseases

Z Xu, B Lv, Y Qin, B Zhang - Cells, 2022 - mdpi.com
Cardiometabolic diseases (CMDs) are currently the leading cause of death and disability
worldwide, and their underlying regulatory mechanisms remain largely unknown. N6 …

Role of N6-methyladenosine modification in pathogenesis of ischemic stroke

H Chang, J Yang, Q Wang, J Zhao… - Expert review of molecular …, 2022 - Taylor & Francis
ABSTRACT Introduction N6-Methyladenosine (m6A), the most common and reversible
mRNA modification, has attracted considerable attention recently, and accumulating …

LncRNA Airn alleviates diabetic cardiac fibrosis by inhibiting activation of cardiac fibroblasts via a m6A-IMP2-p53 axis

T Peng, M Liu, L Hu, D Guo, D Wang, B Qi, G Ren… - Biology Direct, 2022 - Springer
Background Cardiac fibrosis is a leading cause of cardiac dysfunction in patients with
diabetes. However, the underlying mechanisms of cardiac fibrosis remain unclear. This …

N6-Methyladenosine methyltransferase METTL3 promotes angiogenesis and atherosclerosis by upregulating the JAK2/STAT3 pathway via m6A reader IGF2BP1

G Dong, J Yu, G Shan, L Su, N Yu… - Frontiers in cell and …, 2021 - frontiersin.org
Atherosclerosis (AS) is a life-threatening vascular disease. RNA N6-methyladenosine (m6A)
modification level is dysregulated in multiple pathophysiologic processes including AS. In …

RNA modifications in cardiovascular diseases, the potential therapeutic targets

Y Wu, S Zhan, Y Xu, X Gao - Life Sciences, 2021 - Elsevier
More than one hundred RNA modifications decorate the chemical and topological properties
of these ribose nucleotides, thereby executing their biological functions through post …

N6-methyladenosine in macrophage function: a novel target for metabolic diseases

X Zhu, HJ Tang, M Yang, K Yin - Trends in Endocrinology & Metabolism, 2023 - cell.com
Abstract N6-methyladenosine (m 6 A) is one of the most prevalent internal transcriptional
modifications. Evidence has highlighted changes in m 6 A in metabolic disorders and …

Emerging roles of the RNA modifications N6-methyladenosine and adenosine-to-inosine in cardiovascular diseases

V Sikorski, A Vento, E Kankuri - Molecular Therapy-Nucleic Acids, 2022 - cell.com
Cardiovascular diseases lead the mortality and morbidity disease metrics worldwide. A
multitude of chemical base modifications in ribonucleic acids (RNAs) have been linked with …

Silencing METTL3 stabilizes atherosclerotic plaques by regulating the phenotypic transformation of vascular smooth muscle cells via the miR-375-3p/PDK1 axis

J Chen, K Lai, X Yong, H Yin, Z Chen, H Wang… - … drugs and therapy, 2023 - Springer
Purpose Atherosclerosis (AS) is a primary cause of cardiovascular diseases. This study
investigated the mechanism of methyltransferase-like 3 (METTL3) in AS plaques via …